Perjeta 420mg/14ml Inj. 1`s

A qualified oncology team administers it as a slow intravenous infusion, never as a push or bolus.

Perjeta 420mg/14ml Injection Ingredients and Usage

Perjeta 420mg/14ml Injection contains pertuzumab, a humanized monoclonal antibody belonging to the HER2 receptor antagonist drug class. Oncologists prescribe it for HER2 positive metastatic breast cancer in patients who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.

Perjeta 420mg/14ml Injection is also used in early stage HER2 positive breast cancer, given before surgery as neoadjuvant treatment or after surgery as adjuvant treatment. It is always combined with trastuzumab and docetaxel chemotherapy, never given alone.

How Does Perjeta 420mg/14ml Injection Work?

Pertuzumab binds to subdomain II of the HER2 receptor, a protein overexpressed on the surface of HER2 positive breast cancer cells. This binding prevents HER2 from pairing with other HER family receptors, particularly HER3.

By blocking this pairing, Perjeta 420mg/14ml Injection interrupts the downstream signaling that drives tumor cell growth and survival. Combined with trastuzumab, it provides a more complete HER2 blockade and also activates antibody dependent cellular cytotoxicity, helping the immune system attack cancer cells directly.

Perjeta 420mg/14ml Injection Side Effects

Perjeta 420mg/14ml Injection commonly causes digestive and general side effects, often alongside the chemotherapy agents given with it.

• Diarrhea

• Hair loss

• Nausea

• Fatigue

• Skin rash

• Low white blood cell count

• Infusion related reactions such as fever or chills

Warnings

• Perjeta 420mg/14ml Injection can cause subclinical and clinical cardiac failure, including reduced left ventricular ejection fraction and congestive heart failure; cardiac function must be evaluated before and during treatment.

• Exposure to Perjeta 420mg/14ml Injection can cause embryo-fetal death and birth defects; women must use effective contraception during treatment and for a defined period after the last dose.

• Avoid use in patients with a pretreatment ejection fraction below 50 percent, prior heart failure, or high cumulative anthracycline exposure, since safety has not been studied in these groups.

• Perjeta 420mg/14ml Injection must be given as an intravenous infusion only; never administer as an IV push or bolus.

• Discontinue treatment immediately for signs of anaphylaxis or severe hypersensitivity during infusion.

• Patients who received prior anthracyclines or chest radiotherapy face a higher risk of decreased heart function during treatment.

• Do not breastfeed during treatment and for a defined period after the final dose, since safety in lactation has not been established.

Perjeta 420mg/14ml Injection Storage Conditions

Store Perjeta 420mg/14ml Injection refrigerated between 2°C and 8°C, and do not freeze the vial. Protect the vial from light and keep it in its original carton until immediately before use. Store this medicine out of reach of children and ensure only trained healthcare staff handle preparation and administration.